N
SYRS

Nuveen’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Nuveen’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-18,325
Closed -$202K – 3523
2022
Q1 		$202K Buy
18,325
+266
+1% +$4.76K ﹤0.01% 3192
2021
Q4 		$611K Sell
18,059
-1,799
-9% -$72.8K ﹤0.01% 3016
2021
Q3 		$1.01M Buy
19,858
+1,807
+10% +$88.2K ﹤0.01% 2985
2021
Q2 		$984K Buy
18,051
+3,390
+23% +$201K ﹤0.01% 3013
2021
Q1 		$1.1M Buy
14,661
+220
+2% +$22.9K ﹤0.01% 2858
2020
Q4 		$1.57M Sell
14,441
-3,675
-20% -$335K ﹤0.01% 2627
2020
Q3 		$1.6M Sell
18,116
-2,213
-11% -$251K ﹤0.01% 2478
2020
Q2 		$2.17M Buy
20,329
+6,466
+47% +$580K ﹤0.01% 2313
2020
Q1 		$822K Sell
13,863
-200
-1% -$13.6K ﹤0.01% 2599
2019
Q4 		$972K Buy
14,063
+3,299
+31% +$200K ﹤0.01% 2698
2019
Q3 		$1.12M Sell
10,764
-436
-4% -$41.2K ﹤0.01% 2653
2019
Q2 		$1.04M Buy
+11,200
New +$780K ﹤0.01% 2724

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nuveen's SYRS Position: Q2 2022 in Review

Nuveen sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2022, closing a stake of 18,325 shares — an estimated $202K sold.

Nuveen first reported a position in SYRS in Q2 2019 and held it in 12 quarters. The position peaked at $2.17M in Q2 2020. 67 funds tracked by Wall St. Rank hold SYRS as of Q2 2022.

  • Nuveen reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 18,325 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $202K.
  • Nuveen first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
  • Nuveen's Syros Pharmaceuticals, Inc. Common Stock position peaked at $2.17M in Q2 2020.
  • 67 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.